<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">ANTIMICROB AGENTS CHEMOTHER</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC90210</article-id><article-id pub-id-type="pmcid-ver">PMC90210.1</article-id><article-id pub-id-type="pmcaid">90210</article-id><article-id pub-id-type="pmcaiid">90210</article-id><article-id pub-id-type="pmid">11083645</article-id><article-id pub-id-type="doi">10.1128/aac.44.12.3389-3394.2000</article-id><article-id pub-id-type="publisher-id">0208</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Experimental Therapeutics</subject></subj-group></article-categories><title-group><article-title>Activities of Sordarins in Experimental Models of Candidiasis, Aspergillosis, and Pneumocystosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Martinez</surname><given-names initials="A">Antonio</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Aviles</surname><given-names initials="P">Pablo</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jimenez</surname><given-names initials="E">Elena</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Caballero</surname><given-names initials="J">Jesus</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gargallo-Viola</surname><given-names initials="D">Domingo</given-names></name><xref ref-type="author-notes" rid="FN150">*</xref></contrib></contrib-group><aff id="N0x8b90360.0x9e23f18">Research Department, Glaxo Wellcome S.A., 28760 Tres Cantos, Madrid, Spain</aff><author-notes><fn id="FN150"><label>*</label><p>Corresponding author. Mailing address: Glaxo Wellcome, S.A., Parque Tecnol&#243;gico de Madrid, Severo Ochoa, 2, 28760 Tres Cantos, Madrid, Spain. Phone: 34.91.80.70.481. Fax: 34.91.80.70.595. E-mail: <email>dgv28867@glaxowellcome.co.uk</email>.</p></fn></author-notes><pub-date pub-type="ppub"><month>12</month><year>2000</year></pub-date><volume>44</volume><issue>12</issue><issue-id pub-id-type="pmc-issue-id">2491</issue-id><fpage>3389</fpage><lpage>3394</lpage><history><date date-type="received"><day>9</day><month>3</month><year>2000</year></date><date date-type="rev-request"><day>16</day><month>7</month><year>2000</year></date><date date-type="accepted"><day>9</day><month>9</month><year>2000</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>12</month><year>2000</year></date></event><event event-type="pmc-live"><date><day>12</day><month>09</month><year>2002</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-04-29 21:25:31.443"><day>29</day><month>04</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2000, American Society for Microbiology</copyright-statement><copyright-year>2000</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ac003389.pdf"/><abstract><p>Sordarin derivatives represent a new class of antifungal agents that act as potent inhibitors of fungal protein synthesis and possess a broad spectrum of activity. The in vivo activity of <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM193663">GM193663</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM237354">GM237354</ext-link> was studied in mouse models of disseminated candidiasis and aspergillosis and in a rat model of pneumocystosis. The pharmacokinetic behavior of both sordarin derivatives was studied in mice and rats. In all studies, compounds were administered by the subcutaneous route. After a subcutaneous dose of 50 mg/kg of body weight to mice, the maximum level in serum, area under the concentration-time curve, half-life, and clearance for <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM193663">GM193663</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM237354">GM237354</ext-link> were 51.8 and 23 &#956;g/ml, 79.5 and 46 &#956;g &#183; h/ml, 0.8 and 0.85 h, and 21 and 25 ml/h, respectively. Systemic candidiasis and aspergillosis were established in CD-1 male mice infected with <italic>Candida albicans</italic> or <italic>Aspergillus fumigatus</italic>. For systemic candidiasis, compounds were given three times per day for seven consecutive days at 15, 30, 60, or 120 mg/kg/day. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM193663">GM193663</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM237354">GM237354</ext-link> showed dose-related efficacy against <italic>C. albicans</italic>, with 50% effective doses, 1 month after infection, of 25.2 and 10.7 mg/kg/dose, respectively. In experimental infections with <italic>A. fumigatus</italic>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM237354">GM237354</ext-link> was given three times per day at 30, 60, or 120 mg/kg/day for five consecutive days. Animals treated with <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM237354">GM237354</ext-link> demonstrated irregular responses. The survival of animals treated with <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM237354">GM237354</ext-link> was 0, 30, and 0% at 30, 60, and 120 mg/kg/day, respectively. The therapeutic efficacy of <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM193663">GM193663</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM237354">GM237354</ext-link> against <italic>Pneumocystis carinii</italic> was studied in an experimental <italic>P. carinii</italic> pneumonia (PCP) rat model. After a subcutaneous dose of 10 mg/kg given to rats, the maximum level in serum, area under the concentration-time curve, half-life, and clearance for <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM193663">GM193663</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM237354">GM237354</ext-link> were 6.6 and 7.2 &#956;g/ml, 8.5 and 11.8 &#956;g &#183; h/ml, 0.7 and 0.8 h, and 230 and 133 ml/h, respectively. To induce spontaneous PCP, rats were chronically immunosuppressed with dexamethasone. Infected animals were treated twice daily for 10 days at 0.2, 2, or 10 mg/kg/day. The therapeutic effect was estimated by the reduction in the number of cysts in the lungs of treated versus untreated animals. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM193663">GM193663</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM237354">GM237354</ext-link> significantly reduced the mean (&#177; standard deviation) log number of cysts from 7.6 &#177; 0.2 in the untreated group to 4.7 &#177; 0.2 and 4.6 &#177; 0.1, respectively, when the drugs were administered at a dose of 2 mg/kg/day. The log number of cysts was also reduced in infected animals given lower doses of the compounds (0.2 mg/kg/day). In summary, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM193663">GM193663</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM237354">GM237354</ext-link> are new sordarin derivatives that may potentially play a major role in the treatment of candidiasis and PCP. Further testing with <italic>Aspergillus</italic> in other animal models is warranted.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>